Creative Commons source reading · Clinical neurodiagnostics
A multicentre validation study of the diagnostic value of plasma neurofilament light.
Nicholas J Ashton; Shorena Janelidze; Ahmad Al Khleifat; Antoine Leuzy; Emma L van der Ende; Thomas K Karikari; Andrea L Benedet; Tharick A Pascoal; Alberto Lleó; Lucilla Parnetti; Daniela Galimberti; Laura Bonanni; Andrea Pilotto; Alessandro Padovani; Jan Lycke; Lenka Novakova; Markus Axelsson; Latha Velayudhan; Gil D Rabinovici; Bruce Miller; Carmine Pariante; Naghmeh Nikkheslat; Susan M Resnick; Madhav Thambisetty; Michael Schöll; Gorka Fernández-Eulate; Francisco J Gil-Bea; Adolfo López de Munain; Ammar Al-Chalabi; Pedro Rosa-Neto; Andre Strydom; Per Svenningsson; Erik Stomrud; Alexander Santillo; Dag Aarsland; John C van Swieten; Sebastian Palmqvist; Henrik Zetterberg; Kaj Blennow; Abdul Hye; Oskar Hansson
Originally published in Nature communications · 2021-06-07
From the article
Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.
Abstract
Increased cerebrospinal fluid neurofilament light (NfL) is a recognized biomarker for neurodegeneration that can also be assessed in blood. Here, we investigate plasma NfL as a marker of neurodegeneration in 13 neurodegenerative disorders, Down syndrome, depression and cognitively unimpaired controls from two multicenter cohorts: King's College London (n = 805) and the Swedish BioFINDER study (n = 1,464). Plasma NfL was significantly increased in all cortical neurodegenerative disorders, amyotrophic lateral sclerosis and atypical parkinsonian disorders. We demonstrate that plasma NfL is clinically useful in identifying atypical parkinsonian disorders in patients with parkinsonism, dementia in individuals with Down syndrome, dementia among psychiatric disorders, and frontotemporal dementia in patients with cognitive impairment. Data-driven cut-offs highlighted the fundamental importance of age-related clinical cut-offs for disorders with a younger age of onset. Finally, plasma NfL performs best when applied to indicate no underlying neurodegeneration, with low false positives, in all age-related cut-offs.
Discussion
This study, to the best of our knowledge, includes the largest and most diverse investigation for plasma NfL comprising 2269 participants from CU individuals and 13 neurodegenerative disorders, Down syndrome, and depression. First, our findings corroborate, on a large scale, the globally increased plasma NfL concentration in major neurodegenerative disorders.
Editorial reading guide
- Which patient population and reference standard did the authors use?
- Was the finding validated in a separate cohort, and how might patient selection affect it?
